Target intelligence / Profile preview

Novel transcript antisense to BRAF

Molecular classification
Natural antisense transcript (NAT), Long non-coding RNA (lncRNA)
01

Overview

This transcript is a natural antisense long non-coding RNA that overlaps the BRAF gene locus in reverse orientation. Its primary function is to regulate the expression of BRAF by mechanisms such as transcriptional interference, chromatin modification, and RNA masking, thereby affecting the level and processing of functional BRAF mRNA and, subsequently, protein. It has no known protein product and is not considered a canonical therapeutic target, though its activity can shape disease-relevant BRAF signaling; high expression is associated with cancer prognosis in certain contexts[1][2][3][4].\n\nIf you want to map this to typical target fields in a database, it is best categorized under natural antisense transcripts / non-coding RNAs with regulatory rather than druggable or enzymatic roles.

Other names
ENSG00000289788Novel transcript antisense to BRAFNAT-BRAF
02

Mechanism of action

RNA-based mechanisms such as RNA masking, transcriptional interference, altering chromatin environment, and modulating splicing/stability of BRAF mRNA. May affect sensitivity or expression of protein-coding BRAF, which itself is a drug target.

03

Biological functions

Regulation of gene expressionTranscriptional interferenceRNA masking (altering splicing, stability, localization of the sense BRAF transcript)Chromatin modulation (modulates histone acetylation and deacetylation near sense BRAF promoter)
04

Disease associations

Cancer (via modulation of BRAF expression; indirect role, as NATs can regulate oncogene activity)Other roles are possible given the general functions of antisense RNAs, but direct disease association is currently mainly inferred through BRAF involvement
05

Safety considerations

None directly related to targeting this transcript, as no drugs target it; challenges include specificity and delivery if one were to develop RNA-targeted therapeutics or diagnostics
06

Interacting drugs

None
07

Biomarkers

High expression in certain cancer subtypes correlates with worse outcome (especially kidney renal papillary cell carcinoma via ceRNA and miRNA modulation)Expression levels might be used as a biomarker for BRAF activity modulation, but not directly used clinically as of now

Beyond the preview

Go deeper on Novel transcript antisense to BRAF.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novel transcript antisense to BRAF.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call